MyVisionTest News Archive

Displaying news items tagged with clinical trial (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7   >> Last

CATT trial logo
Jan 15, 2012
The much anticipated CATT study has now been published. The National Eye Institute is to be applauded for having sponsored this landmark trial and for setting a new standard of transparency by submitting most of the raw data on the Internet. Millions of people who cannot afford Lucentis (ranibizumab) now have the benefit of a high level of...

Full Article


CATT trial logo
Jan 14, 2012
For 5 years, patients and clinicians have wrestled with the choice between two drugs for the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF), the cytokine primarily responsible for blood-vessel growth, is inhibited when anti-VEGF drugs are injected repeatedly into the eye, and blindness is...

Full Article


Eylea
Jan 8, 2012
The US Food and Drug Administration (FDA) approved aflibercept ophthalmic solution (Eylea, Regeneron Pharmaceuticals Inc) for the treatment of neovascular ("wet") age-related macular degeneration (AMD) in November 2011. "Eylea is an important new treatment option for adults with wet AMD," said Edward Cox of the FDA. "It is a potentially...

Full Article


CATT trial logo
Jan 8, 2012
Avastin and Lucentis had equivalent effects on visual acuity at 1 year, accirding to the much anticipated Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) research group. Clinical trials have established the efficacy of Lucentis (ranibizumab) for the treatment of neovascular age-related macular degeneration (AMD). In...

Full Article


VEGF-Trap
Sep 20, 2010
The GALILEO study has recently started phase 3 to assess the efficacy and safety of VEGF Trap-Eye in the treatment of macular edema in central retinal vein occlusion, a speaker announced here. "Enrollment of 117 patients from 10 countries was completed in July," Frank Holz, MD, said at the Euretina meeting here preceding the European Society...

Full Article


Lucentis
Aug 29, 2010
Lucentis was safe and effective with quarterly (and then monthly) dosing during the 2-year Phase IIIb PIER study of subjects with neovascular age-related macular degeneration (AMD), accordingto a new report from the study. Lucentis provided significant visual acuity (VA) benefit in patients with AMD-related CNV compared with sham injection....

Full Article


Vitreomacular traction
Jun 27, 2010
ThromboGenics' phase 3 trial evaluating microplasmin for the non-surgical treatment of focal vitreomacular adhesion has met its primary endpoint of resolving vitreomacular adhesion at 1 month, the company announced in a press release. "The ability to cure a significant proportion of patients with a range of retinal disorders, including...

Full Article


AREDS2
Jun 27, 2010
The National Eye Institute at the U.S. National Institutes of Health has launched an ancillary study to its Age-Related Eye Disease Study 2 comparing the ability of Notal Vision's ForeseeHome age-related macular degeneration monitor to aid the early detection of wet AMD to that of standard care, according to a joint press release from the...

Full Article


Diabetes
May 8, 2010
iCo Therapeutics announced that the company's Phase I clinical trial study employing iCo-007 in Diffuse Diabetic Macular Edema will be highlighted in a presentation at the Retinal Physician Symposium 2010. Designed and discovered by ISIS Pharmaceuticals Inc, iCo-007 is a second-generation antisense drug targeting c-Raf kinase for the...

Full Article


The Iluvien insert, shown on a human finger to indicate size
Mar 29, 2010
pSivida Corp., reports that 24-month data from the FAME Phase 3 study for Iluvien (fluocinolone acetonide) therapy of diabetic macular edema (DME) was presented at the Angiogenesis 2010 meeting. Iluvien is an investigational, extended release steroid intravitreal insert that is being developed for the treatment of DME. Each Iluvien insert is...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7   >> Last
Most Popular
Less - past - More